Defectos de la apoptosis en el linfoma cutáneo

-A A +A
Artículo de revisión
Rev Asoc Colomb Dermatol. 2016; 24: 3 (Julio-Septiembre), 174-185

Defectos de la apoptosis en el linfoma cutáneo

Defects in apoptosis in cutaneous lymphoma
Autor(es): 
María Adelaida Quijano
mmvelasquez@yahoo.com
Médica, residente de Dermatología, Sección de Dermatología, Universidad de Antioquia, Medellín, Colombia.
Margarita María Velásquez
Dermatóloga, Ph.D. en Ciencias Básicas Biomédicas; docente de Dermatología, Universidad de Antioquia; Centro de Investigaciones Dermatológicas, CIDERM, Sección de Dermatología, Facultad de Medicina, Universidad de Antioquia, Medellín, Colombia.
Resumen: 

Los linfomas cutáneos primarios se definen como linfomas no Hodgkin que se presentan en la piel, sin evidencia extracutánea de la enfermedad en el momento del diagnóstico y, como regla general, permanecen allí durante al menos seis meses. Diferentes alteraciones de las vías de la apoptosis son responsables en gran medida de la patogénesis de los linfomas cutáneos. Los enfoques terapéuticos futuros deben apuntar a restaurar la expresión del receptor de la muerte, que se deben combinar con moduladores de moléculas inhibidoras y con estimuladores de los demás mecanismos implicados en la apoptosis.

Palabras clave: 
linfoma, cutáneo, células B, células T, apoptosis, vía, intrínseca, extrínseca, tratamiento.

Summary: 

Primary cutaneous lymphomas are defined as non-Hodgkin lymphomas that occur in the skin without evidence of extracutaneous disease at diagnosis, and as a rule remain there for at least six months. Various alterations in apoptosis pathways are largely responsible for the pathogenesis of cutaneous lymphomas. Future therapeutic approaches should aim to death receptor expression, to be combined with modulators of inhibitory molecules and stimulators of other mechanisms involved in apoptosis.

Key words: 
Cutaneous lymphoma, B-cell, T-cell, apoptosis intrinsic pathway, extrinsic pathway, treatment.
PDF del articulo

Referencias

  1. Willemze R, Hodak E, Zinzani PL, Specht L, Ladetto M. Primary cutaneous lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013;24:vi149-54.
  2. Kim YH, Willemze R, Pimpinelli N, Whittaker S, Olsen EA, Ranki A, et al. TNM classification system for primary cutaneous lymphomas other than mycosis fungoides and Sézary syndrome: A proposal of the International Society for Cutaneous Lymphomas (ISCL) and the Cutaneous Lymphoma Task Force of the European Organization of Research and Treatment of Cancer (EORTC). Blood. 2007;110:479-84.
  3. Tchernev G, Cardoso JC, Arseniev L, Okamoto H. Extrinsic apoptotic pathways: A new potential “target” for more sufficient therapy in a case of cutaneous anaplastic large cd30+ alk-T-cell lymphoma. Indian J Dermatol. 2011;56:87-91.
  4. Universidad de Valencia, España; 1997 Fecha de consulta: 14 de septiembre de 2013. Disponible en: http://www.uv.es/derma/CLindex/CLlinfomas/CLlinfomas.htm.
  5. Smith BD, Wilson LD. Cutaneous lymphoma. Curr Probl Cancer. 2008;32:43-87.
  6. Willemze R, Jaffe ES, Burg G, Cerroni L, Berti E, Swerdlow SH, et al. WHO-EORTC classification for cutaneous lymphomas. Blood. 2005;105:3768-85.
  7. Smith BD, Wilson LD. Cutaneous lymphomas. Semin Radiat Oncol. 2007;17:158-68.
  8. Wilson LD, Hinds GA, Yu JB. Age, race, sex, stage, and incidence of cutaneous lymphoma. Clin Lymphoma Myeloma Leuk. 2012;12:291-6.
  9. Hwang ST, Janik JE, Jaffe ES, Wilson WH. Mycosis fungoides and Sézary syndrome. Lancet. 2008;371:945-57.
  10. Deonizio JM, Guitart J. Current understanding of cutaneous lymphoma: Selected topics. Dermatol Clin. 2012;30:749-61, vii-viii.
  11. Markova A, Weinstock MA. Trends in cutaneous lymphoma epidemiology. Clin Lymphoma Myeloma Leuk. 2010;10(Suppl.2):S63-S6.
  12. Hinds GA, Heald P. Cutaneous T-cell lymphoma in skin of color. J Am Acad Dermatol. 2009;60:359-75.
  13. Morales-Suárez-Varela MM, Olsen J, Johansen P, Kaerlev L, Guenel P, Arveux P, et al. Occupational exposures and mycosis fungoides. A European multicentre case-control study (Europe). Cancer Causes Control. 2005;16:1253-9.
  14. Herne KL, Talpur R, Breuer-McHam J, Champlin R, Duvic M. Cytomegalovirus seropositivity is significantly associated with mycosis fungoides and Sézary syndrome. Blood. 2003;101:2132-6.
  15. Ballanger F, Bressollette C, Volteau C, Planche L, Dreno B. Cytomegalovirus: Its potential role in the development of cutaneous T-cell lymphoma. Exp Dermatol. 2009;18:574-6.
  16. Gemmill R. Cutaneous T-cell lymphoma. Semin Oncol Nurs. 2006;22:90-6.
  17. Pancake BA, Wassef EH, Zucker-Franklin D. Demonstration of antibodies to human T-cell lymphotropic virus-I tax in patients with the cutaneous T-cell lymphoma, mycosis fungoides, who are seronegative for antibodies to the structural proteins of the virus. Blood. 1996;88:3004-9.
  18. Shohat M, Hodak E, Hannig H, Bodemer W, David M, Shohat B. Evidence for the cofactor role of human T-cell lymphotropic virus type 1 in mycosis fungoides and Sézary syndrome. Br J Dermatol. 1999;141:44-9.
  19. Gupta RK, Ramble J, Tong CY, Whittaker S, MacMahon E. Cytomegalovirus seroprevalence is not higher in patients with mycosis fungoides/Sézary syndrome. Blood. 2006;107:1241-2.
  20. van Doorn R, Dijkman R, Vermeer MH, Starink TM, Willemze R, Tensen CP. A novel splice variant of the Fas gene in patients with cutaneous T-cell lymphoma. Cancer Res. 2002;62:5389-92.
  21. Dereure O, Levi E, Vonderheid EC, Kadin ME. Infrequent Fas mutations but no Bax or p53 mutations in early mycosis fungoides: A possible mechanism for the accumulation of malignant T lymphocytes in the skin. J Invest Dermatol. 2002;118:949-56.
  22. Gallardo FP, Ramón M. Diagnóstico y tratamiento de los linfomas cutáneos primarios de células B. Actas Dermosifiliogr. 2004;95:537-47.
  23. García A, Estrach T. Una visión de los linfomas cutáneos primarios de células B. Medicina Cutánea Ibero-Latino-Americana. 2004;32:187-200.
  24. Barragán ZF, Pulido N, Quintal MdJ, López MM. Linfoma cutáneo primario de células grandes B: informe de un caso. Dermatología Cosmética, Médica y Quirúrgica. 2013;11:213-6.
  25. Zöchling N, Pütz B, Wolf p, Kerl H, Cerroni L. Human herpesvirus 8-specific DNA sequences in primary cutaneous B-cell lymphomas. Arch Dermatol. 1998;134:246-7.
  26. Cho SG, Choi EJ. Apoptotic signaling pathways: Caspases and stress-activated protein kinases. J Biochem Mol Biol. 2002;35:24-7.
  27. Kindt TJ, Goldsby RA, Osborne BA. Inmunología de Kuby. Sexta edición. México, D.F: McGraw Hill; 2007; 264-266
  28. Stutz N, Johnson RD, Wood GS. The Fas apoptotic pathway in cutaneous T-cell lymphomas: Frequent expression of phenotypes associated with resistance to apoptosis. J Am Acad Dermatol. 2012;67:1327.e1-10.
  29. Braun FK, Fecker LF, Schwarz C, Walden P, Assaf C, Durkop H, et al. Blockade of death receptor-mediated pathways early in the signaling cascade coincides with distinct apoptosis resistance in cutaneous T-cell lymphoma cells. J Invest Dermatol. 2007;127:2425-37.
  30. Abbas AK, Lichtman AH, Pillai S. Inmunología celular y molecular. 7ª edición. Barcelona, España: Elseviere Saunders; 2012; 255-257.
  31. Kaufmann SH, Hengartner MO. Programmed cell death: Alive and well in the new millennium. Trends Cell Biol. 2001;11:526-34.
  32. Haupt S, Berger M, Goldberg Z, Haupt Y. Apoptosis - the p53 network. J Cell Sci. 2003;116:4077-85.
  33. Zhang CL, Kamarashev J, Qin JZ, Burg G, Dummer R, Dobbeling U. Expression of apoptosis regulators in cutaneous T-cell lymphoma (CTCL) cells. J Pathol. 2003;200:249-54.
  34. Lamkanfi M, Dixit VM. Manipulation of host cell death pathways during microbial infections. Cell Host & Microbe. 2010;8:44-54.
  35. Amaral JD, Xavier JM, Steer CJ, Rodrigues CM. The role of p53 in apoptosis. Discov Med. 2010;9:145-52.
  36. Manfe V, Biskup E, Johansen P, Kamstrup MR, Krejsgaard TF, Morling N, et al. MDM2 inhibitor nutlin-3a induces apoptosis and senescence in cutaneous T-cell lymphoma: Role of p53. J Invest Dermatol. 2012;132:1487-96.
  37. Contassot E, French LE. Targeting apoptosis defects in cutaneous T-cell lymphoma. J Invest Dermatol. 2009;129:1059-61.
  38. Wu J, Siddiqui J, Nihal M, Vonderheid EC, Wood GS. Structural alterations of the FAS gene in cutaneous T-cell lymphoma (CTCL). Arch Biochem Biophys. 2011;508:185-91.
  39. Rieux-Laucat F, Le Deist F, Hivroz C, Roberts IA, Debatin KM, Fischer A, et al. Mutations in Fas associated with human lymphoproliferative syndrome and autoimmunity. Science. 1995;268:1347-9.
  40. Contassot E, French LE. Epigenetic causes of apoptosis resistance in cutaneous T-cell lymphomas. J Invest Dermatol. 2010;130:922-4.
  41. Djerbi M, Screpanti V, Catrina AI, Bogen B, Biberfeld P, Grandien A. The inhibitor of death receptor signaling, FLICE-inhibitory protein defines a new class of tumor progression factors. J Exp Med. 1999;190:1025-32.
  42. Contassot E, Kerl K, Roques S, Shane R, Gaide O, Dupuis M, et al. Resistance to FasL and tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in Sézary syndrome T-cells associated with impaired death receptor and FLICE-inhibitory protein expression. Blood. 2008;111:4780-7.
  43. Wozniak MB, Piris MA. Cutaneous T-cell lymphoma: Two faces of the same coin. J Invest Dermatol. 2010;130:348-51.
  44. Dereure O, Portales P, Clot J, Guilhou JJ. Decreased expression of Fas (APO-1/CD95) on peripheral blood CD4+ T lymphocytes in cutaneous T-cell lymphomas. Br J Dermatol. 2000;143:1205-10.
  45. Weshahy H, Mahgoub D, El-Eishy N, El-Tawdy AM, Bassiouny DA, Hunter N, et al. Bcl-2 expression in mycosis fungoides before and after PUVA therapy. Photodermatol Photoimmunol Photomed. 2010;26:107-9.
  46. Nevala H, Karenko L, Vakeva L, Ranki A. Proapoptotic and antiapoptotic markers in cutaneous T-cell lymphoma skin infiltrates and lymphomatoid papulosis. Br J Dermatol. 2001;145:928-37.
  47. Wu J, Nihal M, Siddiqui J, Vonderheid EC, Wood GS. Low FAS/CD95 expression by CTCL correlates with reduced sensitivity to apoptosis that can be restored by FAS upregulation. J Invest Dermatol. 2009;129:1165-73.
  48. Zoi-Toli O, Vermeer MH, De Vries E, van Beek P, Meijer CJ, Willemze R. Expression of Fas and Fas-ligand in primary cutaneous T-cell lymphoma (CTCL): Association between lack of Fas expression and aggressive types of CTCL. Br J Dermatol. 2000;143:313-9.
  49. Wu J, Wood GS. Reduction of Fas/CD95 promoter methylation, upregulation of Fas protein, and enhancement of sensitivity to apoptosis in cutaneous T-cell lymphoma. Arch Dermatol. 2011;147:443-9.
  50. Kelly-Sell MJ, Kim YH, Straus S, Benoit B, Harrison C, Sutherland K, et al. The histone deacetylase inhibitor, romidepsin, suppresses cellular immune functions of cutaneous T-cell lymphoma patients. Am J Hematol. 2012;87:354-60.
  51. Tiffon C, Adams J, van der Fits L, Wen S, Townsend P, Ganesan A, et al. The histone deacetylase inhibitors vorinostat and romidepsin downmodulate IL-10 expression in cutaneous T-cell lymphoma cells. Br J Pharmacol. 2011;162:1590-602.
  52. Jones CL, Wain EM, Chu CC, Tosi I, Foster R, McKenzie RC, et al. Downregulation of Fas gene expression in Sézary syndrome is associated with promoter hypermethylation. J Invest Dermatol. 2010;130:1116-25.
  53. Lamprecht B, Kreher S, Mobs M, Sterry W, Dorken B, Janz M, et al. The tumour suppressor p53 is frequently nonfunctional in Sézary syndrome. Br J Dermatol. 2012;167:240-6.
  54. Wang Y, Su M, Zhou LL, Tu P, Zhang X, Jiang X, et al. Deficiency of SATB1 expression in Sézary cells causes apoptosis resistance by regulating FasL/CD95L transcription. Blood. 2011;117:3826-35.
  55. Grzanka A, Grzanka D, Gagat M, Tadrowski T, Sokolowska-Wojdylo M, Marszalek A, et al. Correlation of SATB1 expression with clinical course of cutaneous T-cell lymphomas. Pol J Pathol. 2012;63:101-5.
  56. Sors A, Jean-Louis F, Pellet C, Laroche L, Dubertret L, Courtois G, et al. Down-regulating constitutive activation of the NF-kappaB canonical pathway overcomes the resistance of cutaneous T-cell lymphoma to apoptosis. Blood. 2006;107:2354-63.
  57. Sors A, Jean-Louis F, Begue E, Parmentier L, Dubertret L, Dreano M, et al. Inhibition of IkappaB kinase subunit 2 in cutaneous T-cell lymphoma down-regulates nuclear factor-kappaB constitutive activation, induces cell death, and potentiates the apoptotic response to antineoplastic chemotherapeutic agents. Clin Cancer Res. 2008;14:901-11.
  58. Ferenczi K, Ohtola J, Aubert P, Kessler M, Sugiyama H, Somani AK, et al. Malignant T cells in cutaneous T-cell lymphoma lesions contain decreased levels of the antiapoptotic protein Ku70. Br J Dermatol. 2010;163:564-71.
  59. Wollina U. Cutaneous T cell lymphoma: Update on treatment. Int J Dermatol. 2012;51:1019-36.
  60. Duhovic C, Child F, Wain EM. Management of cutaneous T-cell lymphoma. Clin Med. 2012;12:160-4.
  61. Al-Yacoub N, Fecker LF, Mobs M, Plotz M, Braun FK, Sterry W, et al. Apoptosis induction by SAHA in cutaneous T-cell lymphoma cells is related to downregulation of c-FLIP and enhanced TRAIL signaling. J Invest Dermatol. 2012;132:2263-74.
  62. Zhang C, Li B, Gaikwad AS, Haridas V, Xu Z, Gutterman JU, et al. Avicin D selectively induces apoptosis and downregulates p-STAT-3, bcl-2, and survivin in cutaneous T-cell lymphoma cells. J Invest Dermatol. 2008;128:2728-35.
  63. Zhang C, Li B, Zhang X, Hazarika P, Aggarwal BB, Duvic M. Curcumin selectively induces apoptosis in cutaneous T-cell lymphoma cell lines and patients’ PBMCs: Potential role for STAT-3 and NF-kappaB signaling. J Invest Dermatol. 2010;130:2110-9.
  64. Fink-Puches R, Wolf IH, Zalaudek I, Kerl H, Cerroni L. Treatment of primary cutaneous B-cell lymphoma with rituximab. J Am Acad Dermatol. 2005;52:847-53.
  65. Fernández-Guarino M, Ortiz-Romero PL, Fernández-Misa R, Montalbán C. Rituximab in the treatment of primary cutaneous B-cell lymphoma: A review. Actas Dermosifiliogr. 2014;105:438-45.
  66. Morales AV, Advani R, Horwitz SM, Riaz N, Reddy S, Hoppe RT, et al. Indolent primary cutaneous B-cell lymphoma: Experience using systemic rituximab. J Am Acad Dermatol. 2008;59:953-7.
Goltz syndrome
Rev Asoc Colomb Dermatol. 2016; 24: 3 (Julio-Septiembre), 237-240
Tinea nigra palmaris
Rev Asoc Colomb Dermatol. 2016; 24: 3 (Julio-Septiembre), 230-234
Cutaneous periorificial tuberculosis, when to suspect it? Case report and review of the literature
Rev Asoc Colomb Dermatol. 2016; 24: 3 (Julio-Septiembre), 226-229
Conradi-Hünermann-Happle syndrome
Rev Asoc Colomb Dermatol. 2016; 24: 3 (Julio-Septiembre), 223-225
Gorlin-Goltz syndrome, report of two cases
Rev Asoc Colomb Dermatol. 2016; 24: 3 (Julio-Septiembre), 216-220
Bullous systemic lupus erythematosus with slow response to dapsone.
Rev Asoc Colomb Dermatol. 2016; 24: 3 (Julio-Septiembre), 211-215
Generalized bullous pigmented fixed drug eruption
Rev Asoc Colomb Dermatol. 2016; 24: 3 (Julio-Septiembre), 206-208
Histocytosis, a practical view for the dermatologist
Rev Asoc Colomb Dermatol. 2016; 24: 3 (Julio-Septiembre), 186-203
Defects in apoptosis in cutaneous lymphoma
Rev Asoc Colomb Dermatol. 2016; 24: 3 (Julio-Septiembre), 174-185
Oxidation and antioxidants: facts and controversies
Rev Asoc Colomb Dermatol. 2016; 24: 3 (Julio-Septiembre), 162-173
.
Rev Asoc Colomb Dermatol. 2016; 24: 3 (Julio-Septiembre), 160-161.

PATROCINADORES PRINCIPALES

  • MEDIVELIUS
  • SIEGFRIED
  • MEDIHEALTH
  • SESDERMA
  • PERCOS
  • MD FARMACIA MAGISTRAL
  • EPIDERMIQUE
  • ISDIN
  • GALDERMA